ABOS · Acumen Pharmaceuticals, Inc.
$2.67
+0.12 (+4.71%)
At close · Aug 14
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current operating plan, we expect that our current balance of cash and cash equivalents and marketable securities will fund our operations into early 2027, but we believe it will not be enough to fund our operations for at least 12 months from the date of issuance of our financial statements included in this Quarterly Report on Form 10-Q. Our cash forecast contains estimates and assumptions related to our ongoing clinical trial and other research and development expenses, and we cannot predict the amount or timing of all expenditures with certainty. Accordingly, we have concluded that substantial doubt exists about our ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Market Cap
$193.09M
Shares
72.32M
Weekly off-exchange (dark pool / OTC) trading volume reported to FINRA under its OTC/ATS Transparency data. ATS volume is executed on alternating trading systems (dark pools); non-ATS OTC is other over-the-counter dealer volume. The off-exchange share is total off-exchange volume as a percentage of consolidated weekly trading volume for the same Monday–Friday week.
Off-Exchange Volume History
| Week Start | ATS Volume | Non-ATS OTC Volume | Total Off-Exchange | % of FINRA Weekly Volume |
|---|---|---|---|---|
| 2026-07-06 | 229,757 | 285,613 | 515,370 | 34.0% |
| 2026-06-29 | 285,270 | 546,559 | 831,829 | 38.5% |
| 2026-06-22 | 352,282 | 1,287,010 | 1,639,292 | 22.7% |
| 2026-06-15 | 283,473 | 422,090 | 705,563 | 30.2% |
| 2026-06-08 | 272,705 | 409,009 | 681,714 | 41.4% |
| 2026-06-01 | 225,867 | 437,875 | 663,742 | 40.3% |
| 2026-05-25 | 153,448 | 309,911 | 463,359 | 44.3% |
| 2026-05-18 | 223,955 | 538,915 | 762,870 | 36.6% |
| 2026-05-11 | 171,913 | 533,917 | 705,830 | 46.7% |
| 2026-05-04 | 256,044 | 307,286 | 563,330 | 42.1% |
| 2026-04-27 | 203,605 | 321,953 | 525,558 | 40.4% |
| 2026-04-20 | 323,345 | 337,838 | 661,183 | 39.0% |
| 2026-04-13 | 307,490 | 508,075 | 815,565 | 41.5% |
| 2026-04-06 | 400,942 | 336,922 | 737,864 | 30.1% |
| 2026-03-30 | 403,579 | 609,247 | 1,012,826 | 44.7% |
| 2026-03-23 | 445,753 | 850,461 | 1,296,214 | 39.0% |
| 2026-03-16 | 702,000 | 4,181,403 | 4,883,403 | 41.8% |
| 2026-03-09 | 203,752 | 534,879 | 738,631 | 45.2% |
| 2026-03-02 | 263,619 | 599,753 | 863,372 | 50.2% |
| 2026-02-23 | 137,358 | 701,532 | 838,890 | 49.5% |
| 2026-02-16 | 85,725 | 383,560 | 469,285 | 50.3% |
| 2026-02-09 | 167,801 | 502,505 | 670,306 | 42.8% |
| 2026-02-02 | 276,301 | 901,106 | 1,177,407 | 46.3% |
| 2026-01-26 | 1,137,189 | 12,561,084 | 13,698,273 | 60.9% |
| 2026-01-19 | 44,685 | 265,620 | 310,305 | 46.6% |
| 2026-01-12 | 87,296 | 519,781 | 607,077 | 57.1% |
| 2026-01-05 | 135,688 | 624,701 | 760,389 | 52.7% |
| 2025-12-29 | 79,447 | 332,286 | 411,733 | 57.1% |
| 2025-12-22 | 44,243 | 441,045 | 485,288 | 64.4% |
| 2025-12-15 | 81,194 | 407,388 | 488,582 | 58.4% |
| 2025-12-08 | 74,135 | 299,068 | 373,203 | 52.4% |
| 2025-12-01 | 101,482 | 309,190 | 410,672 | 56.0% |
| 2025-11-24 | 57,396 | 327,523 | 384,919 | 52.4% |
| 2025-11-17 | 57,246 | 356,434 | 413,680 | 54.7% |
| 2025-11-10 | 130,803 | 384,975 | 515,778 | 58.1% |
| 2025-11-03 | 83,364 | 330,940 | 414,304 | 40.7% |
| 2025-10-27 | 182,125 | 471,889 | 654,014 | 42.2% |
| 2025-10-20 | 146,179 | 862,780 | 1,008,959 | 49.3% |
| 2025-10-13 | 132,876 | 808,086 | 940,962 | 57.9% |
| 2025-10-06 | 269,330 | 1,782,206 | 2,051,536 | 59.6% |
| 2025-09-29 | 162,169 | 1,280,486 | 1,442,655 | 61.9% |
| 2025-09-22 | 320,141 | 1,630,171 | 1,950,312 | 53.3% |
| 2025-09-15 | 88,373 | 298,910 | 387,283 | 50.3% |
| 2025-09-08 | 84,359 | 333,422 | 417,781 | 65.2% |
| 2025-09-01 | 52,926 | 216,077 | 269,003 | 58.0% |
| 2025-08-25 | 94,600 | 353,011 | 447,611 | 42.4% |
| 2025-08-18 | 141,869 | 559,906 | 701,775 | 51.1% |
Showing 1–47 of 47 weeks
Key facts
CIK
1576885
CUSIP
00509G209
13F (30d)
93 filings
93 filers
Visit website
Investor relations